Platelets Levels before and after Surgical Intervention in Patients with Oral and Maxillofacial Tumors at MNH, Tanzania


Background: There are documented effects of platelets on the solid tumors which need further study. The elevated platelet counts have been described for majority of cancers. There is inadequate information of effect of benign and malignant oral and maxillofacial tumors on the regulation of platelets. The aim of this study was to investigate the changes in platelet counts among patients with oral and maxillofacial benign and malignant tumors following surgical interventions. Methods: A descriptive postoperative study was done whereby patients with benign and malignant oral and maxillofacial tumors who met the inclusion criteria were included. The included patients were those who had no history of blood transfusion prior, during or after surgery, not on haemoglobin-boosting or bone marrow suppressing medications, not seropositive to human immunodeficiency virus also without clinical findings suggestive of lymphadenopathy, splenomegaly, ecchymosis and petechiae. Demographic data, Platelet counts and haemoglobin levels before and after surgery were documented and analysed by chi-square test and values were considered to be significant if p < 0.05. Results: A total of 61 patients were included in the study. The mean age of participants was 37.03 ± 16.6 years with range of 7 to 77 years. Majority 82.5% (n = 52) had benign tumors with a leading diagnosis of ameloblastoma followed by ossifying fibroma. In general there was an increase of platelet counts following surgery from the mean of 276.38 ± 109.40 K/uL to 308.51 ± 117.24 K/uL. Looking at benign and malignant separately, following surgery there was an increase of platelet counts for benign tumors (278.87 ± 106.37 to 305.96 ± 123.12) but a decrease for malignant tumors group (282.33 ± 147.03 to 232 ± 78.48). The haemoglobin level changed from the mean of 12.60 ± 1.71 g/dl before surgery to 11.69 ± 1.70 g/dl after surgery. Conclusion: The mean postoperative increase in platelet counts in benign and malignant tumors was due to healing process of the wound following surgery while the postoperative decrease in platelets counts in malignant tumors was due to effect of tumor removal which diminished the production of platelets activating factors. Malignant tumors produce platelets activating factors which are necessary for them to grow. Also, the difference in postoperative platelets counts in benign and malignant oral and maxillofacial tumors could be attributed by different biological behavior of benign and malignant tumors and hence different interactions of platelets to these tumors.

Share and Cite:

Moshy, J. , Sohal, K. , Owibingire, S. and Augustino, A. (2015) Platelets Levels before and after Surgical Intervention in Patients with Oral and Maxillofacial Tumors at MNH, Tanzania. Surgical Science, 6, 7-11. doi: 10.4236/ss.2015.61002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Buergy, D., Wenz, F., Groden, C. and Brookman, M.A. (2012) Tumor-Platelet Interaction in Solid Tumors. International Journal of Cancer, 130, 2747-2760.
[2] Ho-Tin-Noé, B., George, T. and Wegner, D.D. (2009) Platelets: Guardians of Tumor Vasculature. Cancer Research, 69, 5623-5626.
[3] Nash, G.F., Turner, L.F., Scully, M.F. and Kakkar, A.K. (2002) Platelets and Cancer. The Lancet Oncology, 3, 425-430.
[4] Pinedo, H.M., Verheul, H.M., D’Amato, R.J. and Folkman, J. (1998) Involvement of Platelets in Tumor Angiogenesis. The Lancet, 352, 1775-1777.
[5] Zur, R.L. (1872) Pathologischen des Blutes. Arch Anatphysiol Wissesch Med, 39, 237-249.
[6] Billroth, T. (1978) Lectures on Surgical Pathology and Therapeutics: A Handbook for Students and Practitionersed. The New Sydenham Society, London.
[7] Dominguezi, I., Crippa, S., Thayer, S.P., Hung, Y.P., Ferron, C.R., Warshaw, A.L. and Fernandez-Del, C.C. (2008) Peoperative Platelet Count and Survival Prognosis in Resected Pancreatic Ductal Carcinoma. World Journal of Surgery, 32, 1051-1056.
[8] Bambace, N.M. and Holmes, C.E. (2011) The Platelet Contribution to Cancer Progression. Journal of Thrombosis and Haemostasis, 9, 237-249.
[9] Pretramaggiori, G., Scherer, S.S., Cervi, D., Klement, G. and Orgill, D.P. (2008) Tumors Stimulate Platelets Delivery of Angiogenic Factors in Vitro: An Unexpected Benefit. American Journal of Pathology, 173, 1609-1616.
[10] Sun, N.C., Mcfee, W.M., Hum, G.J. and Weiner, J.M. (1979) Haemostatic Abnormalities in Malignancy; A Prospective Study of One Hundred Eight Patients. Part I. Coagulation Studies. American Journal of Clinical Pathology, 71, 10-16.
[11] Blom, J.W., Vanderschoot, J.P.M., Oostinder, M.J., Osanto, S., Van Der Meer, F.J.M. and Rosendaa, F.R. (2006) Incidence of Venous Thrombosis in a Large Cohort of 66,329 Cancer Patients: Results of a Record Linkage Study. Journal of Thrombosis and Haemostasis, 4, 529-535.
[12] Manegold, P.C., Hutter, J., Pahemik, S.A., Messmer, K. and Delliani, M. (2003) Platelet-Endothelial Interaction in Tumor Angiogenesis and Microcirculation. Blood, 101, 1970-1976.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.